Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MX3LbY5ie2ViQYPzZZk> NGLr[lk{OCCvaX6= NEH1W2hKdmirYnn0bY9vKG:oIGDBVnAyKHerdHigSWM2OCCxZjCwMlAxOiEQvF2= NGjFSmEyQTh6OEe2NC=>
Jurkat NFzxW3JMcW6jc3WgRZN{[Xl? NHPYcVQ6PiCq MUXEUXNQ MnPOTY5pcWKrdHnvckBw\iCSQWLQNUBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4VtdCC4aXHibYxqfHlid3n0bEBGSzVyIH;mJFMh|ryP MVGyN|g2ODF7OR?=
Capan1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTwO|IhcA>? Mn\HSG1UVw>? MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO NHXUXlEzPDN7OEO4Ny=>
DT40 NH\oNVhEgXSxdH;4bYMhSXO|YYm= NYX2OW5GPzJiaB?= NIf1PYtFVVOR NEPlVG5EgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ NG\he2QzPDl{MkW4Oy=>
ML-1 Mn[0RZBweHSxdHnjJGF{e2G7 M4rzVlIvPSEQvF2= MXqyOEBp M1jkb2ROW09? MnPjV5lv\XKpaYP0bYNidGy7IHXubIFv[2W|IGTSRWlNNWmwZIXj[YQh[XCxcITvd4l{KGmwIF3MMVEh[2WubIO= MUWyOFg6PTF|NR?=
HCT-116 NF3scWxMcW6jc3WgRZN{[Xl? MnTPNE42KM7:TR?= NYrWU2d6OjRiaB?= MmrBVGFTWCCjY4Tpeol1gSCmZXPy[YF{\XN? M2rZOFI{ODV2MkGz
UM-SCC1 NULw[FNzS3m2b4TvfIlkKEG|c3H5 NUfXNW5OOTBizszN NY\YcHZWOjRiaB?= MoPVVoVlfWOnczD0bIUh[2WubDD2bYFjcWyrdIm= NH3ENYQzOTlzMk[yNC=>
FaDu MXTDfZRwfG:6aXOgRZN{[Xl? MV:xNEDPxE1? NETRT4wzPCCq NWKxTXk5WmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> MWGyNVkyOjZ{MB?=
PC-3 M2ToOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm5OWdXOTBizszN Mon2TY5lfWOnczDhJJNq\26rZnnjZY51KGmwaHnibZRqd25iaX6gZ49td267IH\vdo1ifGmxbtMg NFjjU5kzOTV5MUmxNi=>
EoL-1-cell MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\mfGlEPTB;MT6wO|k5KM7:TR?= NWrpd5BnW0GQR1XS
NCI-SNU-5 NGXvcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHxc3pKSzVyPUOuNVI5PDFizszN MkDlV2FPT0WU
BV-173 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLKOVh{UUN3ME21MlQ2PDB7IN88US=> MoC3V2FPT0WU
HCC1806 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XKNGlEPTB;NT63OVE4OyEQvF2= Mn\JV2FPT0WU
COLO-680 Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHkZ3NKSzVyPU[uNlE1ODZizszN MYTTRW5ITVJ?
HCC2218 M1qx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHSOIFKSzVyPUeuO|k4ODRizszN NEfYVpNUSU6JRWK=
SK-MEL-24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TtT2lEPTB;Nz64NVkzPCEQvF2= M4KzTnNCVkeHUh?=
NCI-H720 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRThwNEO2NFMh|ryP NIGxZoVUSU6JRWK=
KASUMI-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRThwOEmyOlYh|ryP MkLVV2FPT0WU
HAL-01 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjyTWM2OD17Lki4OlIh|ryP M4fCc3NCVkeHUh?=
CAL-33 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTLTWM2OD1zMD60N|Qh|ryP NX\rSWhrW0GQR1XS
SK-MEL-1 M1fqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV21UWZ7UUN3ME2xNk41PjZ|IN88US=> NV25dIlOW0GQR1XS
Ramos-2G6-4C10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxfVBKSzVyPUGyMlQ4PTJizszN M3XhbnNCVkeHUh?=
KY821 M2H2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF{LkS4OUDPxE1? M1TFO3NCVkeHUh?=
HEC-1 NV;TXFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjBU4ZKSzVyPUGyMlkyQTZizszN MWjTRW5ITVJ?
SK-NEP-1 NIHTRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XQV2lEPTB;MUOuNVY3KM7:TR?= MUXTRW5ITVJ?
MN-60 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M163TmlEPTB;MUOuOVM5QSEQvF2= MVnTRW5ITVJ?
DU-145 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13DbmlEPTB;MUOuPVA2OyEQvF2= MVnTRW5ITVJ?
EW-3 NGTNcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF2LkW1OlUh|ryP NIrjfYdUSU6JRWK=
OS-RC-2 M3z6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWydppGUUN3ME2xOU46PTh7IN88US=> Ml;5V2FPT0WU
RPMI-8226 NVKyXXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF4LkKwOFIh|ryP NVvyWlVmW0GQR1XS
ChaGo-K-1 M{jzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj3TWM2OD1zNj61N|I2KM7:TR?= NW[0OWFbW0GQR1XS
DEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS4TWpFUUN3ME2xOk43PzF5IN88US=> M2LSNHNCVkeHUh?=
GP5d NWCyVYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED1OW1KSzVyPUG3MlA2OyEQvF2= NUj6b3d5W0GQR1XS
COLO-668 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF5Lk[yPVQh|ryP NGPlem5USU6JRWK=
H9 M3mw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF6LkK4N|Mh|ryP NGXNV2VUSU6JRWK=
NKM-1 NHWyUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH62RZZKSzVyPUG4MlUyOTlizszN NFWxOGNUSU6JRWK=
KYSE-150 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\MPZdKSzVyPUG4Mlk6QDZizszN M13EZnNCVkeHUh?=
Daoy NFv6R5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIryXIRKSzVyPUG5MlU3PDlizszN NWLPd3ZrW0GQR1XS
ECC10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFziZllKSzVyPUKwMlc1PTVizszN NXr6b5kzW0GQR1XS
A388 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJzLkmwPVEh|ryP MYjTRW5ITVJ?
MHH-NB-11 NYfUT2N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULj[FVtUUN3ME2yN{4yOzZ|IN88US=> MWfTRW5ITVJ?
HCC1937 M4[1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrxR2ZuUUN3ME2yOE44PDZizszN NIr6OFBUSU6JRWK=
TGBC11TKB NVP1dolMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz2NHZKSzVyPUK1MlY5PjNizszN M{LWfnNCVkeHUh?=
CTV-1 NVrEdHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjMO2ZKSzVyPUK1Mlg6PjlizszN MWjTRW5ITVJ?
NCI-H2029 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvFe2JZUUN3ME2yOk41OjN6IN88US=> NVX1eJF3W0GQR1XS
HLE NXj5bJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj0TWM2OD1{Nz6wOVQh|ryP MkP0V2FPT0WU
NCI-H1693 M3i4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtTWM2OD1{Nz6yPFk5KM7:TR?= NVPaUJE6W0GQR1XS
HCC70 NXTVcZp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ5LkeyOFYh|ryP MWPTRW5ITVJ?
BEN NIfP[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKwTWM2OD1{Nz65OVY3KM7:TR?= MnHKV2FPT0WU
LB771 NYnPWI1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr5bYlKUUN3ME2yPE45Ozd|IN88US=> MVHTRW5ITVJ?
697 M3HPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PrRWlEPTB;MkmuNFI{PSEQvF2= NU\6OVR4W0GQR1XS
LU-139 NHn3TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\QTWM2OD1{OT6zO|Q5KM7:TR?= NEDSTGVUSU6JRWK=
EW-13 NW\YTpEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD1{OT6zPFE1KM7:TR?= MUfTRW5ITVJ?
MOLT-13 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ7LkO4NVQh|ryP MYLTRW5ITVJ?
L-363 NY\DXGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\CTWM2OD1{OT60O|k5KM7:TR?= MnzDV2FPT0WU
EM-2 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXITWM2OD1{OT60PVAyKM7:TR?= M3jzfXNCVkeHUh?=
RS4-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNyLkSyOFEh|ryP NHLkdpBUSU6JRWK=
A2780 M2q2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfaTWM2OD1|MD63OFU4KM7:TR?= M1fETXNCVkeHUh?=
KU812 NUfoZpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHOTWM2OD1|Mj6zOlQzKM7:TR?= M1;oe3NCVkeHUh?=
COLO-684 NHL6do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ZUWVKSzVyPUOzMlM2QTlizszN MoHBV2FPT0WU
MFE-280 NGKxWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTN|LkO4PFkh|ryP MVnTRW5ITVJ?
KG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULqb2VXUUN3ME2zN{43ODBzIN88US=> NYezVYx7W0GQR1XS
JVM-3 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ld49KSzVyPUO1MlU5PjhizszN MnfOV2FPT0WU
MV-4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[3fmlEPTB;M{WuPFQ6QSEQvF2= M2f4SnNCVkeHUh?=
LAMA-84 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLFO|dUUUN3ME2zOk44OzR3IN88US=> M{Xxe3NCVkeHUh?=
MOLT-16 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN4Lkm1NkDPxE1? M2H3W3NCVkeHUh?=
H4 M{flOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN5LkW2O{DPxE1? NVXaOnl6W0GQR1XS
T47D NUfTUmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKyTplKSzVyPUO3MlcxOThizszN NHzPZ2NUSU6JRWK=
CAL-54 NVLDfYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HRUWlEPTB;M{euPVY3KM7:TR?= Mn7KV2FPT0WU
SW982 M2LyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHnTWM2OD1|OD6wPVk5KM7:TR?= MX3TRW5ITVJ?
IGROV-1 NXezSnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpW2lEPTB;M{muN|MxPCEQvF2= MXXTRW5ITVJ?
NB14 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyeHZKSzVyPUSwMlcxOzFizszN NH\zdpVUSU6JRWK=
HCC1187 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\0e2lEPTB;NEGuNlc4OSEQvF2= M2PPS3NCVkeHUh?=
SBC-1 M{PqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiwTWM2OD12MT6zNFY{KM7:TR?= Mm\hV2FPT0WU
KARPAS-45 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHyO4FKSzVyPUSxMlQ5OThizszN NX3xTGJiW0GQR1XS
MOLT-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXOfndZUUN3ME20Nk4zPTN6IN88US=> M3n2OXNCVkeHUh?=
JVM-2 NEm4T4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvSXZhwUUN3ME20Nk46OjB5IN88US=> NFTXT3NUSU6JRWK=
A4-Fuk MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTR|LkW2PVEh|ryP NHXFUWxUSU6JRWK=
MDA-MB-361 NGPHUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\6T2lEPTB;NEOuPFQyPCEQvF2= MX7TRW5ITVJ?
BALL-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKyO5d6UUN3ME20N{46PTN{IN88US=> MV3TRW5ITVJ?
T98G MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DZbGlEPTB;NESuPFUyPyEQvF2= NFrKbIpUSU6JRWK=
Mo-T M33oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrOXYNUUUN3ME20OU43Ozh7IN88US=> NGWzVXhUSU6JRWK=
MHH-PREB-1 M2KwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOyTWM2OD12NT63OVg2KM7:TR?= M2KwNXNCVkeHUh?=
ALL-PO M{frdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTR5LkO3PVEh|ryP NYPFcmJPW0GQR1XS
NCI-H510A Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L5UWlEPTB;NEeuPVA{PCEQvF2= Mn7VV2FPT0WU
ML-2 NIDhSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOzPWVUUUN3ME20PU44QDV4IN88US=> MXnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03044795 Not yet recruiting Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2018 Phase 2
NCT03581292 Recruiting Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma National Cancer Institute (NCI) October 31 2018 Phase 2
NCT03289910 Recruiting Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia National Cancer Institute (NCI) June 8 2018 Phase 2
NCT02831179 Withdrawn Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IV Merkel Cell Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) December 2017 Phase 1
NCT03032614 Withdrawn Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio September 30 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID